Maverix Medical Expands the Narwhal™ Cryo Portfolio with FDA Clearance of the Narwhal Pro

MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ -- Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.

Like the Narwhal Cryoprobe, cleared June 30, 2026, the Narwhal Pro Cryoprobe is powered by a single-use N₂O cartridge, allowing the fully disposable system to be used without purchasing or servicing a cryosurgical console. It also has a similar sharp, radiopaque tip and is compatible with bronchoscopes with a working channel inner diameter of 2 mm or larger. Narwhal Pro’s working length, however, is optimized for shorter bronchoscopes that are 600 mm or shorter, and it includes adapters to connect directly with Olympus, Fuji, and Pentax scopes. It also features sheath and probe advancement handle controls for precise cryoprobe placement.

Sign up for Blog Updates